173 related articles for article (PubMed ID: 14578679)
1. Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
ten Tije AJ; Synold TW; Spicer D; Verweij J; Doroshow JH; Sparreboom A
Invest New Drugs; 2003 Aug; 21(3):291-8. PubMed ID: 14578679
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
Chico I; Kang MH; Bergan R; Abraham J; Bakke S; Meadows B; Rutt A; Robey R; Choyke P; Merino M; Goldspiel B; Smith T; Steinberg S; Figg WD; Fojo T; Bates S
J Clin Oncol; 2001 Feb; 19(3):832-42. PubMed ID: 11157037
[TBL] [Abstract][Full Text] [Related]
4. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
van Asperen J; van Tellingen O; Sparreboom A; Schinkel AH; Borst P; Nooijen WJ; Beijnen JH
Br J Cancer; 1997; 76(9):1181-3. PubMed ID: 9365166
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
7. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.
Fellner S; Bauer B; Miller DS; Schaffrik M; Fankhänel M; Spruss T; Bernhardt G; Graeff C; Färber L; Gschaidmeier H; Buschauer A; Fricker G
J Clin Invest; 2002 Nov; 110(9):1309-18. PubMed ID: 12417570
[TBL] [Abstract][Full Text] [Related]
8. Distribution of paclitaxel in plasma and cerebrospinal fluid.
Gelderblom H; Baker SD; Zhao M; Verweij J; Sparreboom A
Anticancer Drugs; 2003 Jun; 14(5):365-8. PubMed ID: 12782943
[TBL] [Abstract][Full Text] [Related]
9. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
Lee CK; Choi JS
Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
[TBL] [Abstract][Full Text] [Related]
10. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
Kang MH; Figg WD; Ando Y; Blagosklonny MV; Liewehr D; Fojo T; Bates SE
Clin Cancer Res; 2001 Jun; 7(6):1610-7. PubMed ID: 11410497
[TBL] [Abstract][Full Text] [Related]
11. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).
Callies S; de Alwis DP; Harris A; Vasey P; Beijnen JH; Schellens JH; Burgess M; Aarons L
Br J Clin Pharmacol; 2003 Jul; 56(1):46-56. PubMed ID: 12848775
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Malingré MM; Beijnen JH; Rosing H; Koopman FJ; van Tellingen O; Duchin K; Ten Bokkel Huinink WW; Swart M; Lieverst J; Schellens JH
Cancer Chemother Pharmacol; 2001 Apr; 47(4):347-54. PubMed ID: 11345652
[TBL] [Abstract][Full Text] [Related]
13. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
van Zuylen L; Verweij J; Nooter K; Brouwer E; Stoter G; Sparreboom A
Clin Cancer Res; 2000 Jul; 6(7):2598-603. PubMed ID: 10914699
[TBL] [Abstract][Full Text] [Related]
14. Oral delivery of taxanes.
Malingré MM; Beijnen JH; Schellens JH
Invest New Drugs; 2001 May; 19(2):155-62. PubMed ID: 11392449
[TBL] [Abstract][Full Text] [Related]
15. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.
Hubensack M; Müller C; Höcherl P; Fellner S; Spruss T; Bernhardt G; Buschauer A
J Cancer Res Clin Oncol; 2008 May; 134(5):597-607. PubMed ID: 17932689
[TBL] [Abstract][Full Text] [Related]
16. Effects of cysteine on the pharmacokinetics of paclitaxel in rats.
Lee YK; Han SY; Chin YW; Choi YH
Arch Pharm Res; 2012 Mar; 35(3):509-16. PubMed ID: 22477198
[TBL] [Abstract][Full Text] [Related]
17. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats.
Li X; Choi JS
Int J Pharm; 2007 Jun; 337(1-2):188-93. PubMed ID: 17267149
[TBL] [Abstract][Full Text] [Related]
18. Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar.
Ortega I; Rodriguez M; Suarez E; Perez-Ruixo JJ; Calvo R
Pharm Res; 2007 Jul; 24(7):1299-308. PubMed ID: 17380267
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
Advani R; Fisher GA; Lum BL; Hausdorff J; Halsey J; Litchman M; Sikic BI
Clin Cancer Res; 2001 May; 7(5):1221-9. PubMed ID: 11350887
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
